Globus Medical Inc. (GMED)
Is Wall Street Underestimating Globus Medical Stock's Potential?
Here's why we believe Globus Medical (GMED) stock merits attention as a value stock. It's currently trading approximately 33% below its 1-year high and is also trading at a PS multiple that falls below the average over the past 3 years.
GMED vs. SONVY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?
Should You Hold Onto Globus Medical Stock in Your Portfolio for Now?
GMED rides strong musculoskeletal demand and new launches, but faces currency headwinds and fierce competition.
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.
Globus Medical, Inc. (GMED) Q2 2025 Earnings Call Transcript
Globus Medical, Inc. (NYSE:GMED ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Brian J. Kearns - Senior Vice President of Business Development & Investor Relations David C.
Globus Medical (GMED) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Globus Medical (GMED) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Globus Medical (GMED) Beats Q2 Earnings and Revenue Estimates
Globus Medical (GMED) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.75 per share a year ago.
Stay Ahead of the Game With Globus Medical (GMED) Q2 Earnings: Wall Street's Insights on Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Globus Medical (GMED), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GMED Unveils Next-Gen Oscillating System DuraPro: Stock to Gain?
Globus Medical debuts DuraPro with Excelsius integration, boosting its Power Portfolio.
Globus Medical: Obtaining My Backing Again
Globus Medical shares have reset after a soft Q1 and Nevro acquisition, making valuations more attractive despite near-term dilution. The company's strong growth, driven by NuVasive integration and product launches, is offset by margin compression and recent earnings guidance cuts. A $500M buyback, net cash position, and sales multiples below 3x provide downside support and renewed appeal after a 25-30% share price pullback.
GMED Q1 Earnings & Revenues Miss, '25 EPS View Down, Stock Falls
GMED's first-quarter 2025 weak performance reflects soft Enabling Technology deal closures.
